Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: A 24-h treatment option in Parkinson's disease

Basal Ganglia

Volumn 3, Issue 2, 2013, Pages 127-130

  Todorova, Antoniya ^a   Martinez Martin, Pablo ^b   Martin, Anne ^a   Rizos, Alexandra ^a   Reddy, Prashanth ^a   Chaudhuri, K Ray ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Apomorphine infusion; Parkinson's disease; Rotigotine patch

Indexed keywords

APOMORPHINE; ROTIGOTINE;

ADULT; APATHY; ARTICLE; ATTENTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HUMAN; MEMORY; MOOD; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; NON MOTOR SYMPTOMS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT ASSESSMENT; PDQ 8; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL FUNCTION; SKIN MANIFESTATION; SLEEP; TRANSDERMAL PATCH; UNIFIED PARKINSON DISEASE RATING SCALE PART 3;

EID: 84878465561     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2013.02.002     Document Type: Article

References (14)

1. Poewe W., Wenning G.K. Apomorphine: an underutilized therapy for Parkinson's disease. Movement Disorders 2000, 15(5):789-794.
2. Chaudhuri K.R., Clough C. Subcutaneous apomorphine for Parkinson's disease. Effective yet underused. British Medical Journal 1998, 316:641.
3. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffman M., Swinn L., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Movement Disorders 2005, 20(2):151-157.
4. Reuter I., Ellis C.M., Chaudhuri K.R. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurologica Scandinavica 1999, 100:163-167.
5. Trenkwalder C., Kies B., Rudsinska M., Fine J., Nikl J., Honczarenko K., et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomised, placebo-controlled study (RECOVER). Movement Disorders 2011, 26(1):90-99.
6. Canesi M., Mariani C., Isaias I.U., Pezzoli G. Night-time use of Rotigotine in advanced Parkinson's disease. Functional Neurology 2010, 25(4):201-203.
7. Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861-870.
8. Martinez-Martin P., Reddy P., Antonini A., Henriksen T., Katzenschlager R., Odin P., et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. Journal of Parkinson's Disease 2011, 1:197-203.
9. Martinez-Martin P., Rodriguez-Blazquez C., Abe K., Bhattacharyya K.B., Bloem B.R., Carod-Artal F.J., et al. International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology 2009, 73:1584-1591.
10. Kazis L., Anderson J., Meenan R. Effect sizes for interpreting changes in health status. Medical Care 1989, 27:178-189.
11. Norman G.R., Sloan J.A., Wyrwich K.W. Interpretation of changes in health-related quality of life. The remarkable universality of half a standard deviation. Medical Care 2003, 41:582-592.
12. Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M.M., Chaudhuri K.R. The impact of non motor symptoms on health-related quality of life of patients with Parkinson's disease. Movement Disorders 2011, 26:399-406. On Behalf of the NMSS Validation Group.
13. Stocchi F., Vacca L., Berardelli A., Onofrj M., Manfredi M., Ruggieri S. Dual dopamine agonist treatment in Parkinson's disease. Journal of Neurology 2003, 250:822-826.
14. Di Marco A., Appiah-Kubi L., Chaudhuri K.R. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opinion on Pharmacotherapy 2002, 3(10):1481-1487.